Baseline characteristics
| Autoantibody testing positive (n=388) | Autoantibody testing negative (n=1168) | P value | |
| Sex (column % (row %)) | |||
| Male | 43.8% (20.9%) | 55.1% (79.1%) | <0.001 |
| Female | 56.2% (29.3%) | 45.0% (70.7%) | |
| Age (years) | 51.5±10.8 | 52.3±10.5 | 0.21 |
| BMI (n=208/730) | 28.7±7.5 | 28.3±6.7 | 0.49 |
| History of tobacco use (n=194/675) | 45.4% | 51.9% | 0.11 |
| History of alcohol use (n=147/531) | 23.1% | 27.9% | 0.25 |
| Race (column % (row %)) | |||
| White | 54.3% (22.3%) | 61.0% (77.8%) | 0.11 |
| Asian | 14.2% (27.1%) | 12.2% (72.9%) | |
| Black | 10.3% (31.3%) | 7.3% (68.8%) | |
| Hispanic Ethnicity | 21.2% (26.0%) | 19.5% (74.0%) | |
| Comorbidities | |||
| ≥2 Comorbidities | 24.2% | 28.0% | 0.15 |
| Hypertension | 38.9% | 39.8% | 0.76 |
| Diabetes mellitus | 21.4% | 21.9% | 0.83 |
| Coronary artery disease | 10.3% | 12.7% | 0.22 |
| Chronic obstructive pulmonary disease | 3.4% | 4.5% | 0.32 |
| Chronic kidney disease | 11.9% | 14.7% | 0.16 |
| Extrahepatic manifestations | |||
| Any extrahepatic manifestation | 42.8% | 45.0% | 0.44 |
| Mixed cryoglobulinaemia | 2.3% | 1.9% | 0.59 |
| Depression | 21.4% | 24.7% | 0.19 |
| Sjögren’s syndrome | 0.8% | 0.3% | 0.22 |
| Rheumatoid arthritis | 3.4% | 3.0% | 0.73 |
| Lymphoma | 1.0% | 0.4% | 0.18 |
| Treatment status | |||
| History of HCV antiviral therapy prior to presentation (n=284/679) | 32.0% | 36.1% | 0.23 |
| Received antiviral therapy after presentation | 28.6% | 30.6% | 0.47 |
| Received antiviral therapy at any time | 43.3% (168) | 42.3% (494) | 0.73 |
| SVR achieved (n=149/452) | 37.2% | 47.1% | 0.031 |
| IFN-based therapy | 29.0% | 42.7% | 0.012 |
| DAA therapy | 67.6% | 71.4% | 0.65 |
| HCV genotype (n=281/773) | |||
| 1 Untyped | 15.7% | 11.3% | 0.48 |
| 1a | 34.5% | 36.4% | |
| 1b | 21.0% | 21.9% | |
| 2 | 13.9% | 14.6% | |
| 3 | 12.5% | 12.2% | |
| 4 | 0.7% | 1.9% | |
| 6 | 1.8% | 1.8% | |
| Baseline disease state and severity | |||
| Baseline cirrhosis | 41.5% | 44.3% | 0.34 |
| Baseline history of decompensation | 28.4% | 29.7% | 0.61 |
| Baseline HCC | 4.1% | 4.9% | 0.54 |
| Log10 HCV RNA (IU/mL) (n=263/777) | 4.58±0.02 | 4.59±0.02 | 0.0016 |
| Baseline MELD in patients with baseline cirrhosis | 16.3±7.9 | 16.6±8.6 | 0.83 |
| Baseline CTP (n = 113 /408) | |||
| A | 36.3% | 40.2% | 0.24 |
| B | 35.4% | 39.0% | |
| C | 28.3% | 20.8% | |
BMI, body mass index; CTP, Child-Turcotte-Pugh; DAA, direct acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IFN, interferon; MELD, Model for End-Stage Liver Disease; SVR, sustained virological response.